Zeltia Mulls Options Following EU Rejection Of Sarcoma Drug

Spanish firm Zeltia SA is considering its options following the failure last week of its drug development subsidiary PharmaMar SA to obtain European Union marketing approval for Yondelis (trabectedin) as a third-line treatment for soft tissue sarcoma. (BioWorld International)